How Much Does Trulicity Cost in Texas in 2026?

Texas Retail Pricing for Brand-Name Trulicity

The wholesale acquisition cost (WAC) set by Eli Lilly for Trulicity is $931 per month for a box of four once-weekly pens, regardless of dose strength. That figure holds across Texas retail pharmacies in 2026, with minimal variation between chains like CVS, Walgreens, and H-E-B Pharmacy.

This price applies to patients paying entirely out of pocket without insurance or discount programs. Trulicity's WAC has remained stable since Eli Lilly's last list-price adjustment, though actual out-of-pocket costs vary widely depending on insurance formulary placement and copay assistance. The FDA-approved prescribing information for Trulicity lists four dose strengths (0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg), all priced identically per pen pack.

For context, Trulicity's price sits in the middle of the branded GLP-1 receptor agonist market. Semaglutide (Ozempic) lists at approximately $935 per month, and tirzepatide (Mounjaro) at roughly $1,023 per month. The price gap between these agents is narrow enough that formulary tier placement and copay structure matter far more than list price for most Texas patients.

Pharmacy discount aggregators like GoodRx and RxSaver occasionally show Texas cash prices between $850 and $920 for Trulicity, though these negotiated rates fluctuate weekly and are not guaranteed at every location.

Texas Medicaid Does Not Cover Trulicity for Type 2 Diabetes

Texas Medicaid, administered through the Health and Human Services Commission (HHSC), does not include Trulicity on its preferred drug list for the type 2 diabetes indication as of 2026. This exclusion affects approximately 4.7 million Texas Medicaid enrollees.

The Texas Medicaid Vendor Drug Program maintains a formulary that favors older, less expensive diabetes medications including metformin, sulfonylureas, and certain insulin formulations. GLP-1 receptor agonists as a class have faced inconsistent Medicaid coverage across states. A 2023 analysis published in Diabetes Care found that only 24 of 50 state Medicaid programs covered at least one GLP-1 agonist without prior authorization for type 2 diabetes, and Texas was not among them (Medicaid formulary analysis, Diabetes Care 2023).

Medicaid managed care organizations (MCOs) operating in Texas, including Molina, Superior HealthPlan, and UnitedHealthcare Community Plan, may offer limited exceptions through prior authorization. These exceptions typically require documented failure of two or more first-line agents, an A1C above 8.0% despite adherence, and prescriber attestation of medical necessity. Approval rates for GLP-1 prior authorizations through Texas MCOs have historically been low.

The cardiovascular benefit of dulaglutide demonstrated in the REWIND trial (N=9,901), which showed a 12% reduction in major adverse cardiovascular events (MACE) over a median 5.4-year follow-up, has not yet influenced the Texas Medicaid formulary committee's position (Gerstein HC et al., Lancet 2019). Advocates have argued that REWIND's evidence of cardiovascular risk reduction in patients with and without established cardiovascular disease should prompt reconsideration.

Commercial Insurance Coverage Across Texas

Most large commercial insurers in Texas cover Trulicity on formulary, though tier placement determines the patient's actual cost. Blue Cross Blue Shield of Texas, Aetna, Cigna, and UnitedHealthcare all list dulaglutide on their 2026 formularies, typically at Tier 3 (preferred brand) or Tier 4 (non-preferred brand).

Tier 3 placement generally produces copays of $40 to $75 per fill. Tier 4 pushes that to $100 to $200 per fill before any manufacturer assistance. Some high-deductible health plans (HDHPs), common among Texas employer groups, require patients to meet a full deductible ($1,600 to $3,200 for individuals in 2026) before any drug coverage applies. That means several months of paying the full $931 list price at the pharmacy counter.

Step therapy requirements are common. Many Texas commercial plans require a trial of metformin and at least one other oral agent before approving a GLP-1 receptor agonist. The American Diabetes Association Standards of Care 2024 recommend GLP-1 receptor agonists as second-line therapy after metformin, or as first-line in patients with established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk, which can support appeals when step therapy is denied.

Texas marketplace (ACA) plans through healthcare.gov show even wider variation. Silver-tier plans from Ambetter, Oscar, and Molina Marketplace may cover Trulicity with prior authorization, but Bronze plans with limited drug benefits often exclude GLP-1 agonists entirely.

The Eli Lilly Trulicity Savings Card

Eli Lilly's manufacturer savings program for Trulicity remains active in 2026 and is the single most effective tool for reducing out-of-pocket costs for commercially insured Texas patients.

Eligible patients pay as little as $25 per monthly prescription, with Eli Lilly covering up to $150 per fill. The card can be used for up to 24 months, after which patients must re-enroll. Eligibility requirements include having commercial insurance (not Medicare, Medicaid, or TRICARE), a valid Trulicity prescription, and being a U.S. resident aged 18 or older.

The card works at the point of sale. Patients present the savings card alongside their insurance card at the pharmacy. The insurer processes the claim first, and the savings card covers part or all of the remaining copay or coinsurance. For a patient with a $75 copay, the card reduces their cost to $25. For a patient with a $200 copay, it drops to $50.

There are exclusions. Patients in government-funded programs (Medicare Part D, Medicaid, VA, TRICARE) are ineligible under federal anti-kickback statutes. Cash-pay patients without insurance are also ineligible for the standard savings card, though Eli Lilly offers a separate Lilly Cares patient assistance program for uninsured individuals below 400% of the federal poverty level, which provides Trulicity at no cost.

Compounded Dulaglutide in Texas: Legal Status and Access

Compounded dulaglutide is available through licensed 503A compounding pharmacies in Texas. The Texas State Board of Pharmacy regulates these pharmacies under Chapter 562 of the Texas Pharmacy Act and aligns with federal guidance under Section 503A of the Federal Food, Drug, and Cosmetic Act.

A 503A pharmacy compounds medications based on individual patient prescriptions from a licensed prescriber. The compound must differ from the commercially available product in a clinically meaningful way (different concentration, different delivery vehicle, or allergen removal). Texas has historically taken a permissive stance on peptide compounding compared to states like California, which imposed tighter restrictions in 2024.

Cost is the primary driver of demand. Compounded dulaglutide through Texas 503A pharmacies has been advertised at significantly lower price points than the $931 brand-name product. Some telehealth platforms paired with compounding pharmacies have offered dulaglutide for as low as $150 to $350 per month, though prices vary by pharmacy and dose.

Quality is the primary concern. The FDA's guidance on compounded GLP-1 receptor agonists emphasizes that compounded products do not undergo the same manufacturing quality controls, bioequivalence testing, or stability studies as FDA-approved drugs. Sterility failures in compounded injectables have caused serious adverse events nationally, including a 2023 CDC investigation into contaminated compounded semaglutide linked to hospitalizations (CDC Health Alert Network, 2023).

Patients considering compounded dulaglutide in Texas should verify that the pharmacy holds a current Texas State Board of Pharmacy compounding license, uses United States Pharmacopeia (USP) chapter 797 standards for sterile compounding, and sources pharmaceutical-grade dulaglutide active ingredient from an FDA-registered facility.

Telehealth Access to Trulicity in Texas

Texas permits telehealth prescribing of Trulicity and other GLP-1 receptor agonists. The Texas Medical Board's telehealth rules, updated under Senate Bill 1107, allow physicians to establish a patient-provider relationship and prescribe controlled and non-controlled medications via synchronous audiovisual encounters.

Dulaglutide is not a controlled substance, which simplifies telehealth prescribing. Multiple national telehealth platforms now serve Texas patients for GLP-1 prescriptions, including Ro, Calibrate, Found, and Henry Meds. HealthRX also offers telehealth evaluation for GLP-1 therapy with board-certified physicians licensed in Texas.

A typical telehealth workflow involves completing a medical intake, undergoing a video consultation, receiving a prescription (if appropriate), and having the medication shipped directly or sent to a local Texas pharmacy. Most telehealth platforms accept commercial insurance for the consultation but may not process insurance for the medication itself, requiring patients to use their own pharmacy benefits separately.

The REWIND trial, which enrolled patients across 24 countries including significant U.S. participation, demonstrated that dulaglutide 1.5 mg reduced MACE by 12% (HR 0.88 to 95% CI 0.79-0.99, P=0.026) over 5.4 years of median follow-up compared to placebo in patients with type 2 diabetes and cardiovascular risk factors (Gerstein HC et al., Lancet 2019). This cardiovascular evidence base supports prescribing Trulicity beyond glycemic control alone. Patients with established ASCVD or multiple risk factors may have stronger clinical justification for GLP-1 therapy, which can support both insurance approvals and telehealth prescribing decisions.

How to Lower Your Trulicity Cost in Texas

Several strategies can reduce what you pay. Start with the approach most likely to yield savings based on your insurance status.

Commercially insured patients should first confirm Trulicity's formulary tier with their insurer's pharmacy benefits manager. If dulaglutide sits on a non-preferred tier, the prescriber can submit a formulary exception request citing ADA guidelines and relevant clinical data (REWIND trial, A1C response). Simultaneously, enroll in the Eli Lilly savings card program to reduce remaining copays.

Uninsured patients below 400% FPL should apply to Lilly Cares, which provides Trulicity at no cost. The application requires income documentation and a prescriber signature. Processing takes 4 to 6 weeks.

Medicare Part D enrollees face the most complexity. Trulicity is covered under most Part D plans, but the donut hole (coverage gap) still applies. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, fully effective in 2025, limits total yearly exposure. A patient filling Trulicity monthly at a $200 copay would hit the cap in 10 months, after which Part D covers the remainder. The Medicare Part D coverage framework can be verified through the Medicare Plan Finder tool.

Patients open to compounded alternatives should discuss this option with their prescriber, verify the compounding pharmacy's credentials with the Texas State Board of Pharmacy, and understand that compounded products lack FDA approval status.

Switching GLP-1 agents is another option. If a different GLP-1 (semaglutide, liraglutide, tirzepatide) sits on a lower formulary tier with a given insurer, therapeutic substitution may cut costs while maintaining the same drug class benefits. The ADA Standards of Care support flexible agent selection within the GLP-1 class based on patient-specific factors including cost.

Dulaglutide Clinical Profile: What Texas Prescribers Should Know

Dulaglutide is a once-weekly GLP-1 receptor agonist approved for two indications: improvement of glycemic control in adults with type 2 diabetes, and reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.

The AWARD clinical trial program established dulaglutide's efficacy across multiple comparator studies. AWARD-1 (N=978) demonstrated that dulaglutide 1.5 mg reduced A1C by 1.51% from baseline at 26 weeks versus 0.46% for placebo (Wysham C et al., Diabetes Care 2014). AWARD-11 subsequently established the higher 3.0 mg and 4.5 mg doses, showing incremental A1C reductions of 1.71% and 1.87% respectively at 36 weeks (Frias JP et al., Lancet Diabetes Endocrinol 2021).

Weight loss with dulaglutide is moderate compared to semaglutide. REWIND participants on dulaglutide 1.5 mg lost a mean of 2.95 kg over the study period, while SUSTAIN-6 participants on semaglutide 1.0 mg lost 3.6 kg over a comparable 2-year period. Patients whose primary goal is weight reduction may achieve greater results with semaglutide 2.4 mg (Wegovy), which produced 14.9% mean body weight loss at 68 weeks in STEP-1 (N=1,961) (Wilding JPH et al., NEJM 2021).

The most common adverse effects are gastrointestinal: nausea (12.4%), diarrhea (8.9%), vomiting (6.0%), and abdominal pain (6.5%) per the prescribing label. These effects are dose-dependent and typically diminish within 4 to 8 weeks. The prescribing information carries a boxed warning regarding thyroid C-cell tumors based on rodent studies, though no causal link has been established in humans.

Dulaglutide's once-weekly dosing and autoinjector pen design reduce injection burden. The pen requires no reconstitution or needle attachment. This simplicity supports adherence, which a 2020 retrospective analysis in Diabetes, Obesity and Metabolism linked to better A1C outcomes and lower healthcare utilization in real-world type 2 diabetes populations (Nguyen H et al., Diabetes Obes Metab 2020).

Texas prescribers initiating dulaglutide should start at 0.75 mg weekly for four weeks, then titrate to 1.5 mg weekly. If additional glycemic control is needed after at least four weeks on 1.5 mg, the dose can increase to 3.0 mg and then 4.5 mg at four-week intervals per the FDA label.